1. Home
  2. About Us
  3. Divisions / Centres / Units
  4. Gastroenterology and Hepatology
  5. Publications

Publications

Introduction Staff list Research Publications Education Clinical service
  • Lui TKL, Cheung KS, Leung WK. Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study. Hepato Int July 2022. Published Online.
  • Leung WK , Cheung KS, Li B , Law Y K ,Lui TKL Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication. APT 2021 Apr;53(8):864-872.
  • Lui TKL, Hui CK, Tsui VW et al. New insights on missed colonic lesions during colonoscopy through artificial intelligence-assisted real-time detection (with video). Gastrointest Endosc 2021 93(1):193-200
  • Lui TKL, Tsui VWM, Leung WK. Accuracy of artificial intelligence-assisted detection of upper GI lesions: a systematic review and meta-analysis. Gastrointest Endosc 2020; 92: 821-830 e829
  • Lui TKL, Leung WK. Is artificial intelligence the final answer to missed polyps in colonoscopy? World J Gastroenterol. 2020 Sep 21;26(35):5248-5255..
  • Lui TKL, Guo CG, Leung WK. Accuracy of artificial intelligence on histology prediction and detection of colorectal polyps: a systematic review and meta-analysis. Gastrointest Endosc 2020; 92: 11-22 e16
  • Lui TKL, Leung K, Guo CG et al. Impacts of the Coronavirus 2019 Pandemic on Gastrointestinal Endoscopy Volume and Diagnosis of Gastric and Colorectal Cancers: A Population-Based Study. Gastroenterology 2020; 159: 1164-1166 e1163
  • Lui TKL, Wong KKY, Mak LLY, et al. Feedback from artificial intelligence improved the learning of junior endoscopists on histology prediction of gastric lesions. Endosc Int Open 2020;8:E139-E146.
  • Lui TKL, Wong KKY, Mak LLY, et al. Endoscopic prediction of deeply submucosal invasive carcinoma with use of artificial intelligence. Endosc Int Open 2019;7:E514-E520.
  • Cheung KS, Chan EW, Wong AYS, Chen L, Seto WK, Wong ICK, Leung WK. Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. J Natl Cancer Inst 2019;111: 484-489 (2018 impact factor 10.211)
  • Cheung KS, Chen L, Chan EW, Seto WK, Wong ICK, Leung WK. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187897 patients. Gut 2019 [epub ahead of print] (2018 impact factor 17.943)
  • Yuen MF, Gane EJ, Kim DJ, Weilert F, Chan HLY, Lalezari J, Hwang SG, Nguyen T, Flores O, Hartman G, Liaw S, Lenz O, Kakuda TN, Talloen W, Schwabe C, Klumpp K, Brown N. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 2019;156(5):1392-1403.
  • Cheung KS, Chan EW, Chen L, Seto WK, Wong ICK, Leung WK. Diabetes mellitus increases risk of gastric cancer after Helicobacter pylori eradication: a territory-wide study with propensity score analysis. Diabetes Care 2019 [epub ahead of print] (2018 impact factor 15.270)
  • Cheung KS, Chan EW, Wong AYS, Chen L, Seto WK, Wong ICK, Leung WK. Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study. J Natl Cancer Inst 2018;110:743-749 (2018 impact factor 10.211)
  • Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study. Gut 2018;67:28-35 (2018 impact factor 17.943)
  • Cheung KS, Chen L, Seto WK, Leung WK. Epidemiology, characteristics and survival of post-colonoscopy colorectal cancer in Asia: a population-based study. J Gastroenterol Hepatol 2019 [epub ahead of print] (2018 impact factor 3.632)
  • Fung J, Cheung KS, Wong DK, Mak LY, To WP, Seto WK, Lai CL, Yuen MF. Long Term Outcomes and Predictive Scores for Hepatocellular Carcinoma and HBsAg Seroclearance after HBeAg Seroclearance. J Hepatol 2018;68:462-472 (2018 impact factor 18.946)
  • Leung WK, Wong IOL, Cheung KS, Yeung KF, Chan EW, Wong AYS, Chen L, Wong ICK, Graham DY. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology 2018;155:67-75 (2018 impact factor 19.233)
  • Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018;392(10161):2313-2324.
  • Seto WK, Mak SK, Chiu K, Vardhanabhuti V, Wong HF, Leong HT, Lee PSF, Ho YC, Lee CK, Cheung KS, Yuen MF, Leung WK. Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. J Hepatol. 2018 Mar 16. pii: S0168-8278(18)30164-8.
  • Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol 2017;8:e116 (2018 impact factor 4.803)
  • Cheung KS, Seto WK, Fung J, Lai CL, Yuen MF. Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Clin Transl Gastroenterol 2017;8:e100 (2018 impact factor 4.803)
  • Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. World J Gastroenterol 2017;23:7716-7726 (2018 impact factor 3.411)
  • Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. World J Gastroenterol 2017;23:7863-7874 (2018 impact factor 3.411)
  • Cheung KS, Seto WK, Wong DK, Lai CL, Yuen MF. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat 2017;24:654-661 (2018 impact factor 4.016)
  • Fung J, Wong T, Chok K, Chan A, Cheung TT, Dai JW, Sin SL, Ma KW, Ng K, Ng KT, Seto WK, Lai CL, Yuen MF, Lo CM. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology 2017;66(4):1036-1044.
  • Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Lau HY, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology 2017 65:1451-61 (2017 impact factor 14.079)
  • Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu K, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in patients with prior HBV exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014; 32: 3736-43. (2017 impact factor 26.303)
  • Seto WK, Lo YR, Pawlotsky JP, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018; 392:2313-2324 (2017 impact factor 53.254).
  • Seto WK, Sau-Yan Chan T, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EH, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology 2017;65(5);1451-1461.
  • Wooddell CI*, Yuen MF*, Chan HLY, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schuluep T, Xu Z, Lanford RE, Lewis DL. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med 2017;9(409). * co-first author
  • Seto WK, Hui AJ, Wong VW, Wong GL, Liu K, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicenter prospective study. Gut 2015; 64: 667-72. (2017 impact factor 17.016)
  • Seto WK, Wong DH, Chan TY, Hwang YY, Fung J, Liu KS, Gill H, Lam YF, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. Am J Gastroenterol 2016;111(12):1788-1795.
  • Seto WK, Yuen MF.  “Immune tolerance” in HBV infection: danger lurks. Nat Rev Gastroenterol Hepatol 2016 44: 1071-1079. (2017 impact factor 16.990)
  • Chan EW, Lau WC, Leung WK, Mok MT, He Y, Tong TS, Wong IC. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: A population-based study. Gastroenterology 2015;149:586-95.e3
  • Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim AE, Lai CL, Han KH. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol 2015;62(3):526-32.
  • Fung J, Wong DKH, Seto WK, Kopaniszen M, Lai CL, Yuen MF. Hepatitis B surface antigen seroclearance: relationship to hepatitis B e antigen seroclearance and hepatitis B e antigen-negative hepatitis. Am J Gastroenterol 2014;109(11):1764-70.
  • Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label randomized crossover trial. Gut 2014;63:1410-5
  • Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2013 Aug 31.
  • Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 4:709-16. (2017 impact factor 15.040).
  • Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31. 61 (2017 impact factor 14.079)
  • Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol. 2013 Jul;28(7):1095-113
  • Tan VP, Wong BC. Gastric Cancer Chemoprevention: The current evidence Gastroenterology Clinics of North America. 2013 Jun 42(2):299-316
  • Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, Lai CL, Yuen MF. A large case-control study on the predictability of hepatitis B surface antigen three years before HBsAg seroclearance. Hepatology 2012 56: 812-9. 61 (2017 impact factor 14.079)
  • Tan VP, Cheung TK, Wong WM, Chan OO, Hung IFN, Chan P, Chan CK, Fung J, Yuen MF, Wong BCY. Double-Blind, Randomized, Placebo-Controlled Study of four weeks of Sertraline for the Treatment of Functional Dyspepsia. World J Gastroenterol. 2012 Nov 14;18(42):6127-33
  • Zou B, Chim CS, Pang R, Zeng H, Dai Y, Zhang R, Lam CS, Tan VP, Hung IF, Lan HY, Wong BC. XIAP-associated factor 1 (XAF1), a novel target of p53, enhances p53-mediated apoptosis via post-translational modification. Mol Carcinog. 2012 May;51(5):422-32
  • Ma TK, Lam YY, Tan VP, Yan BP. Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol. 2011 Oct;72(4):697-706
  • Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol 2011; 55(3): 522-8. (2017 impact factor 15.040)
  • Tan VP, Wong BC. Helicobacter pylori and gastritis: Untangling a complex relationship 27 years on. J Gast Hep 26 (2011) Suppl. 1; 42–45
  • Tan VP, Wong WM, Cheung TK, Lai KC, Hung IF, Chan P, Pang R, Wong BCY. Treatment of non-erosive reflux disease with proton pump inhibitor in Chinese patients: a randomized controlled trial. J Gastroenterol. 2011 Jul;46(7):906-12
  • Zhang W, Yang Y, Jiang B, Peng J, Tu S, Sardet C, Zhang Y, Pang R, Hung IF, Tan VP, Lam CS, Wang J, Wong BC. XIAP-associated factor 1 interacts with and attenuates the trans-activity of four and a Half LIM protein. Mol Carcinog. 2011 Mar;50(3):199-207
  • Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51:422-30.
  • Lam PK, Ng ML, Cheung TK, Wong BY, Tan VP, Fong DY, Wei WI, Wong BCY. Rabeprazole is effective in treating laryngopharyngeal reflux. Clin Gastroenterol Hepatol. 2010 Sep;8(9):770-6
  • Tan VP, Yan BPY, Hunt RH, Wong BCY. Proton Pump and Clopidogrel: The Case for Watchful Waiting. Journal of Gastroenterology & Hepatology, 2010 Aug;25(8):1342-7
  • Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hsu A, But DY, Cheung TK, Chan P, Yuen JC, Fung FK, Seto WK, Lin CK, Lai CL. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut. 2010; 59:1389-93.
  • Lai CL, Yuen MF. Chronic hepatitis B - new goals, new treatment. N Engl J Med. 2008; 359:2488-91.
  • Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachitorm U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ, and the Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: Current evidence and practice. Lancet Oncol 2008;9:279-287
  • Lai CL, Gane E, Liaw YF, Hsu CW, Thongawat S, Wang YM, Chen YG, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, DiBisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, for the GLOBE Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-88.
  • Lai CL, Yuen MF. The natural history and treatment of CHB: Critical evaluation of treatment criteria and endpoints. Ann Intern Med 2007; 147:58-61.
  • Lau JYW, Leung WK, Wu JCY, Chan FKL. Wong VWS, Chiu PWY, Lee VWY, Lee KKC, Cheung FKY, Siu P, Ng EKW, Sung JJY. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007;356:1631-40.
  • Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-20.
  • Poon TCW, Sung JJY, Chow SM, Ng EKW, Yu ACW, Chu ESH, Hui AMY, Leung WK. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 2006;130:1858-64
  • Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann H-W, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA, and the Telbivudine Phase II Investigator Group. A One-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients with HBeAg-Positive Chronic Hepatitis B. Gastroenterology 2005; 129:528-536.
  • Leung WK, Bai AHC, Chan VYW, Yu J, To KF, Wu JR, Chan KK, Chan MWY, Fu YG, Chan FKL, Sung JJY. Effect of peroxisome proliferators-activated receptor g ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004;53:331-8.
  • Leung WK, Lin SR, Ching JYL, To KF, Ng EKW, Chan FKL, Lau JYW, Sung JJY. Factors predicting progression of gastric intestinal metaplasia: Results of a randomized trial on H. pylori eradication. Gut2004;53:1244-9.
  • Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003; 362:2089-94.
  • Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, Yuen KY, Sung JJ. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125:1011-7.
  • Lai CL, Chien RN, Leung NWY, Chang TT, Kwan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF, Asian Hepatitis Lamivudine Study Groups. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339(2):61-68.
  • Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF. Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency. Clin Gastroenterol Hepatol. 2013; 11:1004-1010 [impact factor: 6.64]
  • Wong DK, Watanabe T, Tanaka Y, Seto WK, Lee CK, Fung J, Lin CK, Huang FY, Lai CL, Yuen MF. Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. PlosOne. 2013; 8:e66920 [impact factor: 3.73]
  • Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013; 58:923-31 [impact factor: 12]
  • Seto WK, Wong DK, Kopaniszen M, Proitsi P, Sham PC, Hung IF, Fung J, Lai CL, Yuen MF. HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. Clin Infect Dis. 2013; 56:1695-1703. [impact factor: 9.37]
  • Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011; 54:829-36 [impact factor: 12]
  • Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis. 2009; 9:256-264. [impact factor: 19.96]
  • Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008; 135:1192-1199. [impact factor: 12.82]
  • Wong DK, Yuen MF, Ngai VWS, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of HBV intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006; 11:909-916. [impact factor: 3.07]
  • Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantitation of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006; 45:553-559. [impact factor: 9.85]
  • Wong DK, Yuen MF, Yuan HJ, Hui CK, Hall JG, Sum SSM, Lai CL. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology. 2004; 40:727-737. [impact factor: 12; citation: 54]